Shares of Zydus Lifesciences Ltd are buying and selling flat after hitting a day’s excessive of Rs 958 on nineteenth June. This comes after the corporate introduced on Wednesday {that a} latest inspection by the US FDA at its oncology injectable facility in Ahmedabad concluded with two observations — none associated to information integrity.
Zydus Lifesciences has introduced that the US FDA has accomplished a follow-up GMP inspection at its oncology injectable plant in Ahmedabad, carried out between ninth and 18th June 2025.
The inspection concluded with two minor observations which might be unrelated to information integrity. The corporate stated it should work intently with the FDA to deal with them rapidly.
This replace comes after Zydus lately acquired an Institution Inspection Report (EIR) for its API manufacturing facility in Ankleshwar, Gujarat.
That inspection carried out from tenth to 14th March 2025 was categorized as ‘No Motion Indicated’ (NAI), which means the FDA discovered no points and closed the inspection.
At 11:12 AM, the shares of Zydus Lifesciences have been buying and selling 0.45% decrease at Rs 953.95 on NSE.
Unicorn Alerts leverages superior AI know-how to give you highly effective market predictions and actionable inventory scans. Obtain the app as we speak and 10x your buying and selling & investing journey!
